RetiSpec

Company Overview

Snapshot

Founded in June 2016 by Roy Kirshon, RetiSpec operates with 11–50 employees. The company has raised $13.55M across 4 funding rounds from 4 investors. In July 2024, RetiSpec closed a funding round to advance the commercialization of its AI-driven eye test for Alzheimer's disease detection.

Business overview

RetiSpec is a medical imaging company focused on developing a noninvasive tool for the early detection of Alzheimer's disease biomarkers in the eye. The company's core technology utilizes hyperspectral imagery in synergy with machine learning and computer vision algorithms to identify unique signatures of Alzheimer's biomarkers rapidly and cost-effectively. RetiSpec aims to enable widespread early detection of Alzheimer's disease, facilitating timely therapeutic interventions to slow or prevent disease progression, primarily serving the digital medical diagnostics sector within the broader health tech and life sciences market.

Strategic signal

In July 2024, RetiSpec secured $10M to accelerate the commercialization of its AI-driven eye test for Alzheimer's disease. This funding signals strong investor confidence in the company's technology and its potential to significantly impact early dementia diagnostics, positioning RetiSpec for expanded market penetration and clinical adoption.

Company Intelligence Q&A

What is RetiSpec's primary focus?

RetiSpec is developing a noninvasive eye scan technology for the early detection of Alzheimer's disease biomarkers, aiming to enable widespread and accessible screening.

When did RetiSpec last raise capital?

In July 2024, RetiSpec closed a $10M funding round to advance the commercialization of its AI-driven eye test for Alzheimer's disease detection. iGan Partners was a lead investor in this round.

Which organizations are collaborating with RetiSpec on Alzheimer's research?

In May 2022, RetiSpec and the Toronto Memory Program were awarded a grant to launch an innovative early detection program for Alzheimer's in Toronto, Canada.

What technology does RetiSpec utilize for its diagnostic tool?

RetiSpec's patented technology combines hyperspectral imagery with machine learning and computer vision algorithms to detect Alzheimer's biomarkers years before clinical symptoms emerge.

Has RetiSpec received any grants?

In April 2023, RetiSpec received a grant, as reported by Yahoo Finance, to support its initiatives in early Alzheimer's detection.